EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Genes and Their Contribution to Breast Cancer Therapy

Andrea Fernández, Yasmín Cura-Cuevas iD, Susana Rojo-Tolosa iD, José María Gálvez-Navas iD, Encarnación González-Flores, Cristina Pérez-Ramírez, Alberto Jiménez-Morales

Pharmaceutics · 22.05.2026 · 18 (6) · 633

DOI: 10.3390/pharmaceutics18060633 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 22.05.2026. Verfasst von Andrea Fernández und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Service, Pharmacogenetics Unit, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Breast cancer (BC) is a highly prevalent neoplasm worldwide. Despite the wide range of therapeutic options currently available, it remains the leading cause of cancer-related mortality among women. Capecitabine, a prodrug of 5-fluorouracil (5-FU), is widely used in the treatment of advanced BC. However, despite its efficacy, capecitabine exhibits considerable interindividual variability in therapeutic response. This study aimed to evaluate the effect of single-nucleotide polymorphisms (SNPs) in genes involved in capecitabine bioactivation on progression-free survival (PFS) in patients with BC.

Methods

An ambispective cohort study was conducted. Four relevant SNPs in the CES1, CDA, and TYMP genes were analyzed in 85 Caucasian patients with BC using real-time polymerase chain reaction (PCR) with TaqMan® probes.

Results

A significant association was observed between shorter PFS and the GA genotype of the CES1 rs71647871 SNP (p = 0.010; HR = 7.46; 95% CI = 1.24–122.52), as well as with the TT genotype of the CDA rs602950 SNP (p = 0.009; HR = 3.50; 95% CI = 1.36–9.03).

Conclusions

These findings suggest that CES1 rs71647871 and CDA rs602950 may serve as predictive biomarkers of capecitabine effectiveness in patients with BC. Further studies involving larger cohorts are needed to validate these findings and generate additional evidence to support their potential implementation in clinical practice.

Schlagwörter

Stichwörter der Autor:innen

bioactivationbreast cancercapecitabinesingle-nucleotide polymorphismssurvival

Autor:innen und Institutionen

  • Pharmacy Service, Pharmacogenetics Unit, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.
  • Instituto de Investigación Biosanitaria ibs., 18012 Granada, Spain.
  • Cancer Registry of Granada, Andalusian School of Public Health, Cuesta del Observatorio 4, Campus Universitario de Cartuja, 18011 Granada, Spain.
  • Center of Biomedical Research, Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology "José Mataix", University of Granada, 18071 Granada, Spain.
  • Pneumology Department, Hospital Universitario Virgen de las Nieves, Avda. de las Fuerzas Armadas 2, 18014 Granada, Spain.
  • Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 18016 Granada, Spain.

ORCID-Profile: Yasmín Cura-Cuevas, Susana Rojo-Tolosa, José María Gálvez-Navas

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Fernández, A., Cura-Cuevas, Y., Rojo-Tolosa, S., Gálvez-Navas, J. M., González-Flores, E., Pérez-Ramírez, C., & Jiménez-Morales, A. (2026). Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Genes and Their Contribution to Breast Cancer Therapy. Pharmaceutics, 18(6), 633. https://doi.org/10.3390/pharmaceutics18060633

Vancouver

Fernández A, Cura-Cuevas Y, Rojo-Tolosa S, Gálvez-Navas JM, González-Flores E, Pérez-Ramírez C, et al. Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Genes and Their Contribution to Breast Cancer Therapy. Pharmaceutics. 2026;18(6):633. doi:10.3390/pharmaceutics18060633

BibTeX
@article{Fernndez2026,
  author = {Fernández, Andrea and Cura-Cuevas, Yasmín and Rojo-Tolosa, Susana and Gálvez-Navas, José María and González-Flores, Encarnación and Pérez-Ramírez, Cristina and Jiménez-Morales, Alberto},
  title = {Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Genes and Their Contribution to Breast Cancer Therapy},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {633},
  doi = {10.3390/pharmaceutics18060633}
}
Kostenlos starten →